Advanced search
1 file | 182.02 KB

Combretastatin A4-phosphate and its potential in veterinary oncology : a review

Eline Abma (UGent) , Sylvie Daminet (UGent) , Pascale Smets (UGent) , Yicheng Ni and Hilde De Rooster (UGent)
Author
Organization
Abstract
For many years, research on anticancer therapy has focussed almost exclusively on targeting cancer cells directly, to selectively kill them or restrict their growth. But limited advances in this strategy have led researchers to shift their attention to other potential targets. Active research is now on-going on targeting tumour stroma. Vascular disrupting agents (VDAs) appear a promising class of anticancer drugs that are currently under investigation as a sole or combined therapy in human cancer patients. This article will briefly touch on the history and biology of Combretastatin A4-Phosphate (CA4P) as a typical example of VDAs and will concentrate on the side effects that can be expected when used in veterinary patients. Particularly, the pathogenesis of these side effects and how they may be prevented and/or treated will be discussed. The purpose of this article is to illustrate the potentials of CA4P as anticancer therapy in veterinary oncology patients.
Keywords
tubulin-binding agent, vascular disrupting agent, Anticancer therapy, combretastatin A4-phosphate, VASCULAR-TARGETING AGENT, ANAPLASTIC THYROID-CARCINOMA, A-4 DISODIUM PHOSPHATE, SOLID TUMOR-THERAPY, INDUCED CELL-DEATH, PHASE IB TRIAL, A4 PHOSPHATE, RADIATION-THERAPY, RADIOIODINATED HYPERICIN, ADVANCED CANCER

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 182.02 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Abma, Eline, Sylvie Daminet, Pascale Smets, Yicheng Ni, and Hilde De Rooster. 2017. “Combretastatin A4-phosphate and Its Potential in Veterinary Oncology : a Review.” Veterinary and Comparative Oncology 15 (1): 184–193.
APA
Abma, Eline, Daminet, S., Smets, P., Ni, Y., & De Rooster, H. (2017). Combretastatin A4-phosphate and its potential in veterinary oncology : a review. VETERINARY AND COMPARATIVE ONCOLOGY, 15(1), 184–193.
Vancouver
1.
Abma E, Daminet S, Smets P, Ni Y, De Rooster H. Combretastatin A4-phosphate and its potential in veterinary oncology : a review. VETERINARY AND COMPARATIVE ONCOLOGY. 2017;15(1):184–93.
MLA
Abma, Eline, Sylvie Daminet, Pascale Smets, et al. “Combretastatin A4-phosphate and Its Potential in Veterinary Oncology : a Review.” VETERINARY AND COMPARATIVE ONCOLOGY 15.1 (2017): 184–193. Print.
@article{7052530,
  abstract     = {For many years, research on anticancer therapy has focussed almost exclusively on targeting cancer cells directly, to selectively kill them or restrict their growth. But limited advances in this strategy have led researchers to shift their attention to other potential targets. Active research is now on-going on targeting tumour stroma. Vascular disrupting agents (VDAs) appear a promising class of anticancer drugs that are currently under investigation as a sole or combined therapy in human cancer patients. This article will briefly touch on the history and biology of Combretastatin A4-Phosphate (CA4P) as a typical example of VDAs and will concentrate on the side effects that can be expected when used in veterinary patients. Particularly, the pathogenesis of these side effects and how they may be prevented and/or treated will be discussed. The purpose of this article is to illustrate the potentials of CA4P as anticancer therapy in veterinary oncology patients.},
  author       = {Abma, Eline and Daminet, Sylvie and Smets, Pascale and Ni, Yicheng and De Rooster, Hilde},
  issn         = {1476-5810},
  journal      = {VETERINARY AND COMPARATIVE ONCOLOGY},
  keyword      = {tubulin-binding agent,vascular disrupting agent,Anticancer therapy,combretastatin A4-phosphate,VASCULAR-TARGETING AGENT,ANAPLASTIC THYROID-CARCINOMA,A-4 DISODIUM PHOSPHATE,SOLID TUMOR-THERAPY,INDUCED CELL-DEATH,PHASE IB TRIAL,A4 PHOSPHATE,RADIATION-THERAPY,RADIOIODINATED HYPERICIN,ADVANCED CANCER},
  language     = {eng},
  number       = {1},
  pages        = {184--193},
  title        = {Combretastatin A4-phosphate and its potential in veterinary oncology : a review},
  url          = {http://dx.doi.org/10.1111/vco.12150},
  volume       = {15},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: